GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial - PubMed
3 days ago
- #long-acting-therapy
- #multiple-sclerosis
- #clinical-trial
- GA Depot is a long-acting glatiramer acetate formulation designed for extended dosing intervals in relapsing multiple sclerosis (RMS) treatment.
- A 52-week, randomized, double-blind, placebo-controlled phase 3 trial evaluated GA Depot's efficacy and safety in 1016 RMS patients.
- GA Depot significantly reduced the annualized relapse rate (ARR) by 30.1% compared to placebo (p = 0.0066).
- The treatment also notably decreased the number of contrast-enhancing lesions (p = 0.0083).
- Injection site reactions were the most common adverse events, mostly mild and self-limited, occurring more frequently with GA Depot (46.1%) than placebo (28.7%).
- GA Depot demonstrated effectiveness in reducing both clinical and radiological disease activity in RMS patients, mirroring the benefits of subcutaneous GA with less frequent dosing.